Histo-molecular characteristics of platinum-sensitive advanced endometrial cancer: data issued from the GINECO UTOLA study

Abstract N°922

Authors: F. JOLY[1], P. JUST[2], D. VAUR[3], B. ASSELAIN[4], C. JEANNE[5], P. FOLLANA[6], C. CORNILA[7], M. FABBRO[8], C. FOA[9], E. BONNET[10], E. KACZMAREK[11], I. COJEAN-ZELEK[12], A. ARNAUD[13], S. ROCHE[14], A. HARDY-BESSARD[15], P. BOUCHAERT[16], D. DULIEGE[17], M. MOURET-REYNIER[18], K. LEROY[19], J. ALEXANDRE[20]

[1]Department of Medical Oncology, Centre François Baclesse, CAEN, FRANCE; [2]Pathology department, Université Paris Cité APHP. Centre, Hôptal Cochin, PARIS, FRANCE; [3]Département de Biopathologie, Centre François Baclesse, CAEN, FRANCE; [4]ARCAGY-GINECO, PARIS, FRANCE; [5]Département de Biopathologie Centre Francois Baclesse, CAEN, FRANCE; [6]Centre Antoine Lacassagne, NICE, FRANCE; [7]Centre Hospitalier Régional d'Orléans, ORLEANS, FRANCE; [8]ICM Regional Cancer Institute of Montpellier, MONTPELLIER, FRANCE; [9]Service d'oncocologie, Hôpital Saint Joseph, MARSEILLE, FRANCE; [10]Groupe Hospitalier Mutualiste de Grenoble, GRENOBLE, FRANCE; [11]Département d'oncologie médicale, Centre Oscar-Lambret, LILLE, FRANCE; [12]Centre Hospitalier Intercommunal de Créteil, FRANCE; [13]Institut du cancer Avignon-Provence, AVIGNON, FRANCE; [14]Institut inter-régional de Cancérologie - Centre Jean Bernard, LE MANS, FRANCE; [15]Medical Oncology Department, CARIO-HPCA and Cooperative Gynecological Cancer Research Group (GINECO), PLERIN, FRANCE; [16]CHU de Poitiers - Hôpital de la Milétrie, POITIERS, FRANCE; [17]Institut de Cancérologie du Gard – CHU de Nîmes, NIMES, FRANCE; [18]Centre Jean Perrin, CLERMONT-FERRAND, FRANCE; [19]Département de médecine génomique des tumeurs et cancers, Université Paris Cité, AP-HP, Hôpital Européen Georges Pompidou, PARIS, FRANCE; [20]Oncologie médicale, Université de Paris Cité, AP-HP, Cochin-Port Royal, PARIS, FRANCE

INTRODUCTION

- Here we present the baseline histo-molecular profile of the platinum-sensitive advanced EC included in the Utola multicenter, randomized phase 2 trial evaluating the efficacy of olaparib as maintenance therapy.

STUDY DESIGN



METHODOLOGY

- 147 patients with objective response (OR) or stable disease (SD) after first line platinum chemotherapy were included.
- IHC (P53 and MMR) and NGS molecular status (including POLE, BRCA1/2 mutations, MSI sensor and genomic instability score [GIScar]) were obtained from archived tumor tissue.
- Molecular subgroups classification:



PATIENTS CHARACTERISTICS

	dMMR N=18 (14%)	P53m N=69 (53%)	NSMP N=43 (33%)	POLE muté N=1	Total N=131 (100%)
Age (years)					
n	18	69	43	1	131
Mean (SD)	65.8 (10.3)	71.7 (7.9)	67.7 (8.9)	84.0 ()	69.6 (8.9)
Pathological type					
n	18	69	43	1	131
Endometrioid	18 (100%)	38 (55.1%)	40 (93.0%)	1 (100%)	97 (74.0%)
Serous	0 (0.0%)	24 (34.8%)	2 (4.7%)	0 (0.0%)	26 (19.8%)
Others	0 (0.0%)	7 (10.1%)	3 (7.0%)	0 (0.0%)	8 (8.2%)
OMS grade					
n	18	69	43	1	131
Low grade (1 or 2)	11 (61.1%)	17 (24.6%)	33 (76.7%)	1 (100%)	62 (47.3%)
High grade (3)	7 (38.9%)	45 (65.2%)	9 (21.0%)	0 (0.0%)	61 (46.6%)
Unknown	0 (0.0%)	7 (10.2%)	1 (2.3%)	0 (0.0%)	8 (6.1%)
Initial FIGO stage (%)					
n	18	69	43	1	131
I/II	9 (50.0%)	20 (28.9%)	16 (37.2%)	1 (100%)	46 (35.1%)
III/IV	7 (38.8%)	41 (59.4%)	17 (39.5%)	0 (0.0%)	65 (49.6%)
Unknown	2 (11.1%)	8 (11.6%)	10 (23.3%)	0 (0.0%)	20 (15.3%)
BR (%)					
n	18	69	43	1	131
CR	4 (22.2%)	27 (39.1%)	4 (9.3%)	1 (100%)	36 (27.5%)
NED	3 (16.7%)	6 (8.7%)	1 (2.3%)	0 (0.0%)	10 (7.6%)
PR	9 (50.0%)	17 (24.6%)	27 (62.8%)	0 (0.0%)	53 (40.5%)
SD	2 (11.1%)	19 (27.5%)	11 (25.6%)	0 (0.0%)	32 (24.4%)
Number of cycles					
n	17	65	38	1	121
4 – 6	17 (100.0%)	63 (96.9%)	36 (94.7%)	0 (0.0%)	117 (96.7%)
6 – 8	0 (0.0%)	2 (3.1%)	2 (5.3%)	1 (100.0%)	4 (3.3%)
Missing data	1	4	5	0	10

NGS RESULTS



MOLECULAR CHARACTERISTICS



RESULTS

- **Complete response according to molecular subgroups:**



- **High concordance between NGS/IHC for P53m and MSI status**



- **GIScar: higher genomic instability for P53m**



CONCLUSION

- More than half of UTOLA trial tumors are associated with poor prognosis molecular profiles.
- A high concordance of NGS MSI/P53 and IHC was observed.
- High platin sensitivity and genomic instability observed in P53m tumors reinforces the rational to evaluate olaparib in this population.

ACKNOWLEDGMENTS

- Thanks to all the patients and their families, investigators, pharmacists, CRA, pathologists, biologists, and all the study team and to Astra Zeneca for their financial support.

ESGO European Society of Gynaecological Oncology | 23rd European Congress on Gynaecological Oncology | Oct 27-30, 2022 | Berlin, Germany

Oral Poster presented at the 23nd ESGO Annual hybrid Meeting, on October 27-30, 2022 in Berlin, Germany.